VITA 34 International AG places 600,000 shares at 15.00 Euro from capital increase – Cash inflow of 9 million Euro facilitates implementation of growth strategy

Vita 34 International AG / IPO

Release of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

Leipzig, March 23, 2007 – As part of its stock market flotation, VITA 34
International AG (ISIN DE000A0BL849), the parent company of VITA 34, the
leading private umbilical cord blood bank in the German-speaking countries,
has placed 600,000 shares from a capital increase, thus securing the
financing of the company’s accelerated growth in the long term. The issue
price for the shares was fixed at 15.00 Euro in agreement with the lead
manager, Concord Effekten AG. The book building span ranged from 14.50 to
17.50 Euro. Initial plans for existing shareholders in VITA 34
International AG to give up shares as part of the flotation were not
followed through. The IPO on the Regulated Market (Prime Standard) of the
Frankfurt Stock Exchange is scheduled for March 27.

The gross inflow of funds amounting to 9 million Euro will enable VITA 34
to finance its planned growth strategy in full and to continue developing
the market for umbilical cord blood banking. VITA 34 concentrates on
manufacturing preparations of autologenous (the body’s own) stem cells, in
which field it currently has a market share in german-speaking territory 
amounting to approx. 66 percent. In international comparison, the German
market still has considerable development potential as regards the
proportion of cord blood storage requested by parents. In coming years,
VITA 34 plans to raise this by significantly increasing interaction with
end-customers and opinion leaders.

Assignments to private investors as part of the offer will be made in
compliance with the 'Basic Principles for the Assignment of Share Emissions
to Private Investors', published on June 7, 2000 by the Stock Exchange
Commission of Experts at the German Federal Ministry of Finance. 82 percent
of shares were allocated to institutional investors, 15 percent to private
investors and approximately 3 percent were allocated preferentially (family
& friends). Through the capital increase, the company’s capital stock rose
to 2,646,500 Euro.


Information and Explaination of the Issuer to this News:

Important Notice:
The press release is directed exclusively to persons who have their
domicile or corporate headquarters in Germany. This press release and the
information contained therein are not intended for dissemination in the
United States of America (USA). In certain legal systems outside of
Germany, among others in the United States of America, Canada, Australia
and Japan, providing access to information of this type may be legally
restricted or prohibited. No responsibility is taken for the correctness of
this information and this information does not constitute any form of
investment advice.
This press release does not represent an offer for sale nor a request to
issue an offer for purchase or for subscription in the shares of Vita 34
International AG, rather it serves informational purposes only. The public
offering is made exclusively on the basis of the published securities
prospectus (including any supplements). The prospectus was approved by the
German Federal Agency for Financial Services Supervision on March 3, 2007
and can be obtained from the internet sites and, or it may be obtained free of charge from Concord
Effekten AG, Grosse Gallusstrasse 60311, 34, Frankfurt am Main, Germany,
and from Vita 34 International AG, Deutscher Platz 04103, Leipzig, Germany.
An investment in the shares of Vita 34 International AG should only be made
on the basis of the prospectus including and supplements.
The shares of Vita 34 International AG may only be sold or offered for sale
in the United States for the account of a 'U.S. person' (as defined in
Regulation S of the U.S. Securities Act of 1933) subsequent to prior
registration according to the regulations of the U.S. Securities Act in its
currently valid version, or without prior registration only based on an
exemption from the registration requirement. The shares have not been and
will not be registered under the U.S. Securities Act.
This press release and the information contained therein are not intended
for dissemination in the United States of America, Canada, Australia or
To the extent prognoses, estimates, opinions or expectations are expressed
or forward-looking statements are made in this press release, these
statements may be associated with known and unknown risks, uncertainties
and other factors that may lead to actual results, the financial situation,
the value development or the results of Vita 34 International AG
significantly deviating from the prognosticated value developments and
The shares of growth companies may present large opportunities, however,
the risks associated with this are inevitable. The shares of growth
companies principally, therefore, are a risk-laden financial investment. A
loss of the investment cannot be excluded. For this reason, this type of
investment is generally more suited as diversification within the context
of a portfolio strategy.

Press/Investor Relations: 
Axel Mühlhaus
Dr. Sönke Knop
edicto GmbH
Zeisselstraße 19
D-60318 Frankfurt
Tel.: +49 (069) 90550552
Fax: +49 (069) 90550577

DGAP 23.03.2007 
Language:     English
Issuer:       Vita 34 International AG
              Deutscher Platz 5a
              04103 Leipzig Deutschland
Phone:        +49(0341)48792-40
Fax:          +49(0341)48792-39
ISIN:         DE000A0BL849
WKN:          A0BL84
Listed:       Geregelter Markt in Frankfurt (Prime Standard)
Notierung vorgesehen / designated to be listed
End of News                                     DGAP News-Service